Innoviva, Inc.
Innoviva, Inc. (NASDAQ: NNVA) is a diversified biopharmaceutical company headquartered in California with a portfolio spanning respiratory royalties, critical care and infectious disease products, and strategic healthcare investments. The company operates through multiple business segments that collectively position… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Innoviva, Inc. does
In the company’s own words
Innoviva, Inc. (NASDAQ: NNVA) is a diversified biopharmaceutical company headquartered in California with a portfolio spanning respiratory royalties, critical care and infectious disease products, and strategic healthcare investments. The company operates through multiple business segments that collectively position it as a player in high-need therapeutic areas.
The company's royalty portfolio generates revenue through partnerships with Glaxo Group Limited (GSK) on respiratory assets including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which treat chronic obstructive pulmonary disease and asthma. Under tiered royalty agreements, Innoviva receives 15 percent on the first $3.0 billion of annual global net sales of RELVAR/BREO ELLIPTA and 5 percent above that threshold, while ANORO ELLIPTA royalties range from 6.5 to 10 percent.
The company's wholly owned critical care and infectious disease platform, Innoviva Specialty Therapeutics, represents a significant operational expansion. This segment includes five commercial products: GIAPREZA for septic shock, XACDURO for carbapenem-resistant Acinetobacter infections, XERAVA for complicated intra-abdominal infections, ZEVTERA for staphylococcus aureus bacteremia and pneumonia, and NUZOLVENCE for uncomplicated gonorrhea. These products address serious hospital-acquired and community-acquired infections with limited treatment options.
Beyond its core operations, Innoviva maintains strategic healthcare investments including a significant stake in Armata Pharmaceuticals, a bacteriophage development company, and economic interests in other healthcare companies through a portfolio approach.
The company's transformation from a pure-play royalty business reflects a disciplined capital deployment strategy focused on areas of significant unmet medical need. This evolution accelerated through acquisitions including Entasis Therapeutics and La Jolla Pharmaceutical in 2022, which anchored the critical care platform, and subsequent licensing agreements such as the ZEVTERA commercialization rights from Basilea. The company's strategy emphasizes maximizing respiratory asset value, growing its infectious disease platform, and efficiently allocating capital to enhance long-term shareholder returns. More information is available at www.innoviva.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BURLINGAME, CA
- Fiscal year end
- December
- CIK
- 1080014
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Innoviva, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Innoviva, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Innoviva, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Innoviva, Inc.’s debt, $15.80M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.13%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Innoviva, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Innoviva, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Innoviva, Inc.'s last four quarterly filings that the numbers alone won't show?”